Home › Myelodysplastic Syndromes › Massachusetts › Worcester
Myelodysplastic Syndromes clinical trials in Worcester, MA
3 studies for Myelodysplastic Syndromes are looking for participants at sites in and around Worcester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- UMass Memorial Medical Center - University Campus, Worcester
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RecruitingObservational study
- Dana Farber Cancer Institute at Milford Regional Medical Center, Milford · 17 mi away
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Worcester
About Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.
More about Myelodysplastic Syndromes on MedlinePlus
Myelodysplastic Syndromes trials in other cities
- Houston, TX43 studies
- Baldwin Park, CA26 studies
- Seattle, WA21 studies
- New York City, NY21 studies
- Washington, DC20 studies
- Boston, MA19 studies
- Tampa, FL19 studies
- Miami, FL17 studies
- Columbus, OH14 studies
- Durham, NC14 studies
- Atlanta, GA13 studies
- Chicago, IL13 studies
Other studies in Worcester
- Non-Small Cell Lung Cancer14 studies
- Lung Cancer11 studies
- Cancer (all types)7 studies
- Breast Cancer6 studies
- Schizophrenia5 studies
- Metastatic Cancer5 studies
- Prostate Cancer5 studies
- Ovarian Cancer5 studies
- Major Depressive Disorder5 studies
- Depression5 studies
- Acute Myeloid Leukemia5 studies
- Urothelial (Transitional Cell) Carcinoma4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.